Flunisolide 氟尼缩松|cas:3385-03-3|西域试剂

Flunisolide 氟尼缩松,99.95%

产品编号：Bellancom-B1121| CAS NO：3385-03-3| 分子式：C₂₄H₃₁FO₆| 分子量：434.50

Flunisolide是一种皮质类固醇, 常用于治疗过敏性鼻炎。Flunisolide的主要作用机制是激活糖皮质激素受体, 意味着它具有抗炎作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-B1121		￥3200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Flunisolide 氟尼缩松

产品介绍

Flunisolide 是一种皮质类固醇，是具有口服活性的糖皮质激素受体 ( Glucocorticoid receptor ) 激活剂，具有抗炎活性。Flunisolide 可诱导嗜酸性粒细胞凋亡 (apoptosis)，可用于哮喘或鼻炎、炎症的相关研究。

生物活性

Flunisolide is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation.

体外研究

Flunisolide (0.1-10 μM, 1 h) inhibits lung fibroblast (Isolated from lung) activation.
Flunisolide (10 μM, 24 h) reduces MMP-9, TIMP-1, TGF-β and fibronectin release by sputum cells (isolated from mild to moderate asthmatics), and induces sputum eosinophil apoptosis.
Flunisolide (0.1-10 µM μM, 24 h) effectively inhibits ICAM-1 expression and GM-CSF and IL-5 release induced by TNF-alpha in BEAS-2B cells.
Flunisolide (115 µM, 0-3 h) can be transported in a polarized way in the apical (ap) to basolateral (bl) direction in Calu-3 cells and is demonstrated to be ATP-dependent^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	Eosinophil
Concentration:	10 μM
Incubation Time:	24 h
Result:	Induced sputum eosinophil apoptosis.

体内研究
(In Vivo)

Flunisolide (Intranasal administration, 0.3–10 µg/mouse, daily, from days 21-27) inhibits lung inflammation, fibrosis, and airway hyper-reactivity, also improves clearance of silica particles from the lungs in silicotic mice.
Flunisolide (Intranasal administration, 0.3–10 µg/mouse, daily, from days 21-27) inhibits silica-induced macrophage and myofibroblast accumulation in the lung tissue.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 µL, particle size 0.5-10 µm)
Dosage:	0.3-10 µg/mouse, daily, from days 21–27
Administration:	Intranasal administration
Result:	Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles. Reduced the number of F4/80 and α-SMA positive cells.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 µL, particle size 0.5-10 µm)
Dosage:	0.3-10 µg/mouse, daily, from days 21–27
Administration:	Intranasal administration
Result:	Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles. Reduced the number of F4/80 and α-SMA positive cells.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss Webster mice (instilled, intranasally, with crystalline silica, 10 mg/50 µL, particle size 0.5-10 µm)
Dosage:	0.3-10 µg/mouse, daily, from days 21–27
Administration:	Intranasal administration
Result:	Reduced both granulomatous response, collagen deposition, concerning granuloma formation caused by silica particles. Reduced the number of F4/80 and α-SMA positive cells.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (287.69 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3015 mL	11.5075 mL	23.0150 mL
5 mM	0.4603 mL	2.3015 mL	4.6030 mL
10 mM	0.2301 mL	1.1507 mL	2.3015 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.79 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.79 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.79 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Tatiana Paula Teixeira Ferreira, et al. Intranasal Flunisolide Suppresses Pathological Alterations Caused by Silica Particles in the Lungs of Mice. Front Endocrinol (Lausanne). 2020 Jun 17;11:388. [Content Brief]

. M Profita, et al. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy. 2004 Sep;59(9):927-32. [Content Brief]

. S Boero, et al. Modulation by flunisolide of tumor necrosis factor-alpha-induced stimulation of airway epithelial cell activities related to eosinophil inflammation. J Asthma. 2010 May;47(4):381-7. [Content Brief]

[4]. B I Florea, et al. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3). Br J Pharmacol. 2001 Dec;134(7):1555-63. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

相关产品

符号	GHS06
信号词	Danger
危害声明	H300
警示性声明	P264-P301 + P310
个人防护装备	Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
危害码 (欧洲)	T+
风险声明 (欧洲)	28
安全声明 (欧洲)	28-36/37-45
危险品运输编码	UN 2811 6.1 / PGI
WGK德国	3
RTECS号	TU3900000

Section 1. Chemical Product and Company Identification
Flunisolide, Anhydrous
Common Name/
Trade Name
Flunisolide, Anhydrous

Section 4. First Aid Measures

Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention.
Skin ContactIn case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove
contaminated clothing and shoes. Wash clothing before reuse. Thoroughly clean shoes before reuse. Get
medical attention.
Serious Skin ContactWash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate
medical attention.
InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious InhalationEvacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or
waistband. Seek medical attention.
IngestionIf swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by
mouth to an unconscious person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical
attention immediately.
Serious IngestionNot available.

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash PointsNot available.
Flammable LimitsNot available.
Products of CombustionThese products are carbon oxides (CO, CO2), halogenated compounds.
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various SubstancesNon-flammable in presence of shocks.
Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
of Various SubstancesRisks of explosion of the product in presence of static discharge: Not available.
Fire Fighting MediaSMALL FIRE: Use DRY chemical powder.
and InstructionsLARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Special Remarks onNot available.
Fire Hazards
Special Remarks on Explosion Not available.
Hazards

Section 6. Accidental Release Measures
Small SpillUse appropriate tools to put the spilled solid in a convenient waste disposal container.
Large SpillPoisonous solid.
Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray to
reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Eliminate all ignition
Flunisolide, Anhydrous

Section 7. Handling and Storage
PrecautionsKeep locked up.. Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk,
evaporate the residue under a fume hood. Ground all equipment containing material. Do not ingest. Do not
breathe dust. Wear suitable protective clothing. In case of insufficient ventilation, wear suitable respiratory
equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid contact with
skin and eyes.
StorageKeep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 25°C (77°F).

Section 8. Exposure Controls/Personal Protection
Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal ProtectionSplash goggles. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spillto avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure LimitsNot available.

Section 9. Physical and Chemical Properties
Physical state and appearance Solid.OdorNot available.
Not available.
Taste
Molecular Weight434.51 g/mole
Not available.
Color
Not available.
pH (1% soln/water)
Boiling PointNot available.
Not available.
Melting Point
Critical TemperatureNot available.
Specific GravityNot available.
Vapor PressureNot applicable.
Vapor DensityNot available.
Not available.
Volatility
Odor ThresholdNot available.
Water/Oil Dist. Coeff.Not available.
Ionicity (in Water)Not available.
Dispersion PropertiesNot available.
SolubilityNot available.

Section 10. Stability and Reactivity Data
StabilityThe product is stable.
Instability TemperatureNot available.
Conditions of InstabilityExcess heat
Incompatibility with various Not available.
substances
Flunisolide, Anhydrous
CorrosivityNot available.
Special Remarks onNot available.
Reactivity
Special Remarks onNot available.
Corrosivity
PolymerizationWill not occur.

Section 11. Toxicological Information
Routes of EntryInhalation. Ingestion.
Toxicity to AnimalsAcute oral toxicity (LD50): >0.5 mg/kg [Mouse].
Chronic Effects on Humans Not available.
Other Toxic Effects onHazardous in case of skin contact (irritant), of ingestion, of inhalation.
Humans
Special Remarks onNot available.
Toxicity to Animals
Special Remarks onMay cause adverse reproductive effects (paternal and maternal effects, fetotoxicity) and birth defects based on
Chronic Effects on Humansanimal data. No human data found at this time.
Special Remarks on otherAcute Potential Health Effects:
Toxic Effects on HumansSkin: May cause skin irritation.
Eyes: May cause eye irritation.
Inhalation: May cause respiratory tract irritation. May cause ulceration of nasal septum.
Ingestion: Harmful if swallowed. May cause gastrointestinal tract irritation. May affect behavior/Central Nervous
system (somnolence). May also affect metabolism (weight loss or decreased weight gain),and blood(aplastic
anemia).

Section 12. Ecological Information
EcotoxicityNot available.
BOD5 and CODNot available.
Products of BiodegradationPossibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
Toxicity of the ProductsThe products of degradation are as toxic as the product itself.
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation

Section 13. Disposal Considerations
Waste DisposalWaste must be disposed of in accordance with federal, state and local environmental
control regulations.
Flunisolide, Anhydrous

Section 14. Transport Information
DOT ClassificationCLASS 6.1: Poisonous material.
Identification: Toxic Solid, Organic, n.o.s. (Flunisolide) UNNA: 2811 PG: III
Not available.
Special Provisions for
Transport
DOT (Pictograms)
HARMFUL
STOW AWAY
FROM
FOODSTUFFS
6

Section 15. Other Regulatory Information and Pictograms
California prop. 65: This product contains the following ingredients for which the State of California has found to
Federal and State
cause cancer, birth defects or other reproductive harm, which would require a warning under the statute:
Regulations
Flunisolide, Anhydrous
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause reproductive harm (female) which would require a warning under the statute: Flunisolide, Anhydrous
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause birth defects which would require a warning under the statute: Flunisolide, Anhydrous
California
California prop. 65: This product contains the following ingredients for which the State of California has found
Proposition 65
to cause birth defects which would require a warning under the statute: Flunisolide, Anhydrous
Warnings
Other RegulationsOSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
DSCL (EEC)R28- Very toxic if swallowed.S1/2- Keep locked up and out of the reach of
R36/38- Irritating to eyes and skin.children.
S28- After contact with skin, wash immediately
with plenty of water.
S36/37- Wear suitable protective clothing and
gloves.
S45- In case of accident or if you feel unwell,
seek medical advice immediately (show the
label where possible).
S46- If swallowed, seek medical advice
immediately and show this container or label.
Health Hazard
HMIS (U.S.A.)2 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
2 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
Flunisolide, Anhydrous
TDG (Canada)
(Pictograms)
6
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent.

SECTION 16 - ADDITIONAL INFORMATION
N/A

Flunisolide 氟尼缩松,99.95%

Flunisolide 氟尼缩松

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询